Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spero Therapeutics (SPRO) Other Accumulated Expenses (2016 - 2025)

Spero Therapeutics' Other Accumulated Expenses history spans 10 years, with the latest figure at $133000.0 for Q4 2025.

  • For Q4 2025, Other Accumulated Expenses rose 10.83% year-over-year to $133000.0; the TTM value through Dec 2025 reached $133000.0, up 10.83%, while the annual FY2025 figure was $133000.0, 10.83% up from the prior year.
  • Other Accumulated Expenses reached $133000.0 in Q4 2025 per SPRO's latest filing, up from $82000.0 in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $1.3 million in Q3 2021 to a low of $82000.0 in Q3 2025.
  • Average Other Accumulated Expenses over 5 years is $391250.0, with a median of $204000.0 recorded in 2021.
  • Peak YoY movement for Other Accumulated Expenses: skyrocketed 468.25% in 2023, then crashed 84.15% in 2024.
  • A 5-year view of Other Accumulated Expenses shows it stood at $1.2 million in 2021, then crashed by 83.17% to $209000.0 in 2022, then rose by 12.92% to $236000.0 in 2023, then plummeted by 49.15% to $120000.0 in 2024, then increased by 10.83% to $133000.0 in 2025.
  • Per Business Quant, the three most recent readings for SPRO's Other Accumulated Expenses are $133000.0 (Q4 2025), $82000.0 (Q3 2025), and $89000.0 (Q2 2025).